arrow
M

Marek Dedecjus

Maria Sklodowska-Curie National Research Institute of Oncology
H指数:18
被引数:1,002

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Score interpretation thresholds for the European Organisation for Research and Treatment of Cancer thyroid cancer quality of life questionnaire (EORTC QLQ-THY34). An international prospective study

欧洲癌症研究与治疗组织甲状腺癌生活质量问卷(EORTC QLQ-THY34)评分解释阈值:一项国际前瞻性研究

2026-10-290
OAAI
P211 - ECE_2319 - Hematological toxicity of radioligand therapy based on personalized dosimetry: interim results of the multicenter DUONEN study

P211 - ECE_2319 - 基于个性化剂量学的放射性配体疗法的血液学毒性:多中心DUONEN研究的阶段性结果

2026-08-100
OAAI
Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial

神经内分泌肿瘤中剂量学指导的肽受体放射性核素治疗: DUONEN试验的临时安全性分析

2025-12-010
OAAI
International Consensus on the Requirements for Definitions of Complete Remission and Recurrence of Differentiated Thyroid Cancer: a Delphi Study (ICON-DTC)

关于分化型甲状腺癌完全缓解和复发的定义要求的国际共识:一项德尔菲研究(ICON-DTC)

2025-12-010
PRE
Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma

欧洲癌症研究与治疗组织 (EORTC) 内分泌工作组关于低风险微乳头状甲状腺癌患者的管理和共同决策的立场文件

2023-01-0111
OAAI